204 related articles for article (PubMed ID: 25990803)
1. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation.
Kawamura K; Hayakawa J; Akahoshi Y; Harada N; Nakano H; Kameda K; Ugai T; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Int J Hematol; 2015 Aug; 102(2):230-7. PubMed ID: 25990803
[TBL] [Abstract][Full Text] [Related]
2. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
[TBL] [Abstract][Full Text] [Related]
3. Varicella Zoster Virus Infection in Children with Autologous Hematopoietic Cell Transplantation: A Retrospective, Single-Center Study in Korea.
Kang JM; Kim JM; Lee JW; Yoo KH; Sung KW; Koo HH; Kim YJ
Biol Blood Marrow Transplant; 2020 May; 26(5):965-971. PubMed ID: 31962166
[TBL] [Abstract][Full Text] [Related]
4. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation.
Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Transpl Infect Dis; 2013 Oct; 15(5):457-65. PubMed ID: 23895431
[TBL] [Abstract][Full Text] [Related]
5. Varicella zoster virus infection after allogeneic hematopoietic cell transplantation in children using a relatively short duration of acyclovir prophylaxis: A retrospective study.
Han SB; Kim SK; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH
Medicine (Baltimore); 2017 Apr; 96(14):e6546. PubMed ID: 28383421
[TBL] [Abstract][Full Text] [Related]
6. Herpes Zoster in Autologous Hematopoietic Cell Transplant Recipients in the Era of Acyclovir or Valacyclovir Prophylaxis and Novel Treatment and Maintenance Therapies.
Sahoo F; Hill JA; Xie H; Leisenring W; Yi J; Goyal S; Kimball LE; Lee I; Seo S; Davis C; Pergam SA; Flowers ME; Liaw KL; Holmberg L; Boeckh M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):505-511. PubMed ID: 28039754
[TBL] [Abstract][Full Text] [Related]
7. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation.
Erard V; Guthrie KA; Varley C; Heugel J; Wald A; Flowers ME; Corey L; Boeckh M
Blood; 2007 Oct; 110(8):3071-7. PubMed ID: 17515400
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of acyclovir prophylaxis against varicella zoster virus disease after allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
Wada-Shimosato Y; Tanoshima R; Hiratoko K; Takeuchi M; Tsujimoto SI; Shiba N; Ito S; Yamanaka T; Ito S
Transpl Infect Dis; 2019 Jun; 21(3):e13061. PubMed ID: 30756465
[TBL] [Abstract][Full Text] [Related]
10. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
[TBL] [Abstract][Full Text] [Related]
11. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.
Boeckh M; Kim HW; Flowers ME; Meyers JD; Bowden RA
Blood; 2006 Mar; 107(5):1800-5. PubMed ID: 16282339
[TBL] [Abstract][Full Text] [Related]
12. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients.
Truong Q; Veltri L; Kanate AS; Hu Y; Craig M; Hamadani M; Cumpston A
Ann Hematol; 2014 Apr; 93(4):677-82. PubMed ID: 24097085
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders.
Kim DH; Messner H; Minden M; Gupta V; Kuruvilla J; Wright J; Lipton J
Transpl Infect Dis; 2008 Apr; 10(2):90-8. PubMed ID: 17605742
[TBL] [Abstract][Full Text] [Related]
14. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir.
Steer CB; Szer J; Sasadeusz J; Matthews JP; Beresford JA; Grigg A
Bone Marrow Transplant; 2000 Mar; 25(6):657-64. PubMed ID: 10734301
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Incidence of Varicella Zoster Virus Disease in Adults Receiving Single-Unit Cord Blood Transplantation.
Fukushi K; Konuma T; Monna-Oiwa M; Isobe M; Kato S; Kuroda S; Takahashi S; Nannya Y
Transplant Cell Ther; 2022 Jun; 28(6):339.e1-339.e7. PubMed ID: 35364334
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients.
Lee YJ; Neofytos D; Kim SJ; Cheteyan L; Huang YT; Papadopoulos EB; Jakubowski AA; Papanicolaou GA
Transpl Infect Dis; 2018 Dec; 20(6):e12977. PubMed ID: 30120866
[TBL] [Abstract][Full Text] [Related]
17. Low-dose acyclovir for prophylaxis of varicella-zoster virus reactivation after hematopoietic stem cell transplantation in children.
Tatebe Y; Ushio S; Esumi S; Sada H; Ochi M; Tamefusa K; Ishida H; Fujiwara K; Kanamitsu K; Washio K; Katsube R; Murakawa K; Zamami Y
Pediatr Blood Cancer; 2022 Dec; 69(12):e29979. PubMed ID: 36151963
[TBL] [Abstract][Full Text] [Related]
18. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group.
Oshima K; Takahashi T; Mori T; Matsuyama T; Usuki K; Asano-Mori Y; Nakahara F; Okamoto S; Kurokawa M; Kanda Y
Transpl Infect Dis; 2010 Oct; 12(5):421-7. PubMed ID: 20626711
[TBL] [Abstract][Full Text] [Related]
19. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
König C; Kleber M; Reinhardt H; Knop S; Wäsch R; Engelhardt M
Ann Hematol; 2014 Mar; 93(3):479-84. PubMed ID: 24318541
[TBL] [Abstract][Full Text] [Related]
20. Severe Herpes Zoster Requiring Intravenous Antiviral Treatment in Allogeneic Hematopoietic Cell Transplantation Recipients on Standard Acyclovir Prophylaxis.
Baumrin E; Cheng MP; Kanjilal S; Ho VT; Issa NC; Baden LR
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1642-1647. PubMed ID: 31004745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
